PDL BioPharma Inc. [NASDAQ: PDLI] jumped around 0.06 points on Wednesday, while shares priced at $2.56 at the close of the session, up 2.40%. The company report on November 12, 2020 that PDL BioPharma Reports 2020 Third Quarter Financial Results and Sets Date To File a Certificate of Dissolution.
– Consummated critical monetization transactions during third quarter, including the sale of its Noden pharmaceutical business and of a basket of royalties to SWK Holdings. Also entered into a settlement agreement with Wellstat. Subsequently completed the spin-off of its medical device company, LENSAR, on October 1, 2020.
– As of September 30, 2020, prior to the spin-off of LENSAR, net assets in liquidation were $494.7 million. Net assets attributable to LENSAR on September 30, 2020 were $112.4 million.
PDL BioPharma Inc. stock is now 2.68% up from its year-to-date (YTD) trading value. PDLI Stock saw the intraday high of $2.565 and lowest of $2.465 per share. The company’s 52-week high price is 3.50, which means current price is +22.49% above from all time high which was touched on 02/13/20.
Compared to the average trading volume of 1.05M shares, PDLI reached a trading volume of 1645951 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about PDL BioPharma Inc. [PDLI]?
Piper Jaffray have made an estimate for PDL BioPharma Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on December 22, 2016. While these analysts kept the previous recommendation, RBC Capital Mkts dropped their target price from $5 to $4. The new note on the price target was released on February 23, 2016, representing the official price target for PDL BioPharma Inc. stock. Previously, the target price had yet another drop from $6 to $5, while RBC Capital Mkts kept a Sector Perform rating on PDLI stock. On November 05, 2015, analysts decreased their price target for PDLI shares from 7 to 6.
The Average True Range (ATR) for PDL BioPharma Inc. is set at 0.09, with the Price to Sales ratio for PDLI stock in the period of the last 12 months amounting to 5.69. The Price to Book ratio for the last quarter was 0.71, with the Price to Cash per share for the same quarter was set at 0.92.
How has PDLI stock performed recently?
PDL BioPharma Inc. [PDLI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.56. With this latest performance, PDLI shares gained by 14.80% in over the last four-week period, additionally sinking by -15.41% over the last 6 months – not to mention a rise of 10.70% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PDLI stock in for the last two-week period is set at 59.95, with the RSI for the last a single of trading hit 75.29, and the three-weeks RSI is set at 55.05 for PDL BioPharma Inc. [PDLI]. The present Moving Average for the last 50 days of trading for this stock 2.52, while it was recorded at 2.49 for the last single week of trading, and 3.01 for the last 200 days.
PDL BioPharma Inc. [PDLI]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and PDL BioPharma Inc. [PDLI] shares currently have an operating margin of -121.55 and a Gross Margin at -9.44. PDL BioPharma Inc.’s Net Margin is presently recorded at -128.59.
Return on Total Capital for PDLI is now -9.01, given the latest momentum, and Return on Invested Capital for the company is -9.54. Return on Equity for this stock declined to -10.64, with Return on Assets sitting at -8.38. When it comes to the capital structure of this company, PDL BioPharma Inc. [PDLI] has a Total Debt to Total Equity ratio set at 4.88. Additionally, PDLI Total Debt to Total Capital is recorded at 4.65, with Total Debt to Total Assets ending up at 4.04. Long-Term Debt to Equity for the company is recorded at 4.72, with the Long-Term Debt to Total Capital now at 4.50.
Reflecting on the efficiency of the workforce at the company, PDL BioPharma Inc. [PDLI] managed to generate an average of -$938,813 per employee. Receivables Turnover for the company is 0.70 with a Total Asset Turnover recorded at a value of 0.07.PDL BioPharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 13.30 and a Current Ratio set at 13.70.
Earnings analysis for PDL BioPharma Inc. [PDLI]
With the latest financial reports released by the company, PDL BioPharma Inc. posted -0.48/share EPS, while the average EPS was predicted by analysts to be reported at 0.05/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -1,060.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PDLI. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for PDL BioPharma Inc. go to 14.00%.
Insider trade positions for PDL BioPharma Inc. [PDLI]
There are presently around $252 million, or 87.50% of PDLI stock, in the hands of institutional investors. The top three institutional holders of PDLI stocks are: BLACKROCK INC. with ownership of 9,813,602, which is approximately -1.489% of the company’s market cap and around 0.90% of the total institutional ownership; DIMENSIONAL FUND ADVISORS LP, holding 9,318,552 shares of the stock with an approximate value of $23.86 million in PDLI stocks shares; and PARK WEST ASSET MANAGEMENT LLC, currently with $23.48 million in PDLI stock with ownership of nearly New of the company’s market capitalization.
Positions in PDL BioPharma Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 53 institutional holders increased their position in PDL BioPharma Inc. [NASDAQ:PDLI] by around 17,437,670 shares. Additionally, 79 investors decreased positions by around 15,160,742 shares, while 32 investors held positions by with 65,829,695 shares. The mentioned changes placed institutional holdings at 98,428,107 shares, according to the latest SEC report filing. PDLI stock had 23 new institutional investments in for a total of 10,263,871 shares, while 29 institutional investors sold positions of 4,901,270 shares during the same period.